The University of Chicago Header Logo

Connection

Harvey M. Golomb to Methotrexate

Back to Details
This is a "connection" page, showing publications Harvey M. Golomb has written about Methotrexate.
Harvey M. Golomb
Connection Strength
0.172
Methotrexate
  1. Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma. Cancer Treat Rep. 1976 Sep; 60(9):1225-30.
    View in: PubMed
    Score: 0.032
  2. The impact on survival by adjuvant chemotherapy and radiation therapy in stage II non-small-cell lung cancer. Am J Clin Oncol. 1992 Oct; 15(5):405-11.
    View in: PubMed
    Score: 0.025
  3. Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. Leukemia. 1990 Feb; 4(2):127-31.
    View in: PubMed
    Score: 0.020
  4. A 10-year experience with combined modality therapy for stage III small cell lung carcinoma. Cancer. 1986 Nov 15; 58(10):2177-84.
    View in: PubMed
    Score: 0.016
  5. The treatment of histiocytic lymphoma. Semin Oncol. 1980 Sep; 7(3):302-9.
    View in: PubMed
    Score: 0.011
  6. Diagnosis, staging, and treatment of the malignant lymphomas. Compr Ther. 1980 Jul; 6(7):48-56.
    View in: PubMed
    Score: 0.011
  7. Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP). JAMA. 1978 Dec 15; 240(25):2743-6.
    View in: PubMed
    Score: 0.009
  8. Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine. Cancer Treat Rep. 1978 Apr; 62(4):567-9.
    View in: PubMed
    Score: 0.009
  9. Combined modality therapy for stage IIIMO non-oat cell bronchogenic carcinoma. Cancer Treat Rep. 1978 Mar; 62(3):327-32.
    View in: PubMed
    Score: 0.009
  10. Letter: Prolonged survival of patients with extensive oat cell carcinoma treated with radiotherapy and cyclophosphamide (NSC-26271), vincristine (NSC-67574), and methotrexate (NSC-7040). Cancer Treat Rep. 1976 Mar; 60(3):221-3.
    View in: PubMed
    Score: 0.008
  11. Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (cyclophosphamide, oncovin, methotrexate, leucovorin, cytosine arabinoside): a 10-year experience in a single institution. J Clin Oncol. 1985 Dec; 3(12):1596-604.
    View in: PubMed
    Score: 0.004
  12. CAMP chemotherapy for metastatic non-oat cell bronchogenic carcinoma. A 7-year experience (1975-1981) with 160 patients. Cancer. 1985 Nov 15; 56(10):2385-90.
    View in: PubMed
    Score: 0.004
  13. Long-term survival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol. 1985 Oct; 3(10):1309-17.
    View in: PubMed
    Score: 0.004
  14. Metastatic non-small cell bronchogenic carcinoma: a randomized trial of sequential vs combination chemotherapy. Eur J Cancer Clin Oncol. 1983 Jan; 19(1):33-8.
    View in: PubMed
    Score: 0.003
  15. VP16-213 in combined modality treatment of small cell carcinoma of the lung. Eur J Cancer Clin Oncol. 1982 Apr; 18(4):343-6.
    View in: PubMed
    Score: 0.003
  16. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med. 1980 Jun; 92(6):785-90.
    View in: PubMed
    Score: 0.003
  17. Letter: Chemotherapy of advanced histocytic lymphomas. Lancet. 1975 May 17; 1(7916):1136.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.